In bid to lower prices, Gottlieb says FDA will take new action to speed approval of biosimilars

(By Adam Feuerstein for STAT)

NEW YORK — Scott Gottlieb, the commissioner of the Food and Drug Administration, is a free-market proponent in a fervently anti-regulatory administration who is trying to lower drug prices by expanding the regulatory reach of the agency. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.